Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2024 | Importance of DNA repair pathway in therapeutic combination strategies

Naoto Ueno • 14 Sep 2024
ESMO 2024
Breast Cancer

Naoto Ueno, MD, PhD, University of Hawai’i Cancer Center, Honolulu, HI, discusses recent preclinical findings from human samples indicating the potential role of DNA repair pathways in the development of therapeutic combinations. While abnormalities in the DNA repair pathway did not emerge as predictive biomarkers for treatment outcomes, this does not rule out the possibility of effective drug combinations. Ongoing research, including studies using liquid and tumor biopsies, will aim to identify predictive biomarkers that may enhance treatment strategies. This interview took place at the European Society for Medical Oncology (ESMO) 2024 Congress in Barcelona, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Naoto Ueno

DESTINY-Breast04: exploring T-DXd and IO combinations in HER2-low breast cancer
1:14
DESTINY-Breast04: exploring T-DXd and IO combinations in HER2-low breast cancer
Naoto Ueno • 14 Sep 2024
DESTINY-Breast04: T-DXd in HER2-low breast cancer regardless of molecular markers
2:31
DESTINY-Breast04: T-DXd in HER2-low breast cancer regardless of molecular markers
Naoto Ueno • 14 Sep 2024
Biomarker-based personalization for HER2-low breast cancer treatment in DESTINY-Breast04
0:45
Biomarker-based personalization for HER2-low breast cancer treatment in DESTINY-Breast04
Naoto Ueno • 14 Sep 2024
What to look out for at SABCS 2022
0:44
What to look out for at SABCS 2022
Naoto Ueno • 6 Dec 2022

Related Videos

How will SARMs fit into the current breast cancer treatment paradigm?
1:14
How will SARMs fit into the current breast cancer treatment paradigm?
Rafael Grochot • 2 Jul 2026
Phase I/II trial of vosilasarm and endocrine therapy in AR+/ER+/HER2− breast cancer
1:35
Phase I/II trial of vosilasarm and endocrine therapy in AR+/ER+/HER2− breast cancer
Rafael Grochot • 2 Jul 2026
HYPORT: does the number of fractions of RNRT impact the typical symptoms experienced?
1:07
HYPORT: does the number of fractions of RNRT impact the typical symptoms experienced?
Sanjoy Chatterjee • 17 May 2026
Design and aim of the HYPORT study in regional nodal breast cancer
1:23
Design and aim of the HYPORT study in regional nodal breast cancer
Sanjoy Chatterjee • 17 May 2026
The content of VJOncology is intended for healthcare professionals